Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib-based induction with or without venetoclax plus anti-CD20 antibody in untreated mantle cell lymphoma
2020-004910-37Phase 2Active
- Sponsor
- LYSARC
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in mantle cell lymphoma (MCL) comparing Ibrutinib + anti-CD20 antibody with Ibrutinib + venetoclax + anti-CD20 antibody (2 arms). Primary endpoint: Minimal residual disease negativity at end of induction. Started Feb 2021; status: active.
02
Drugs
ibrutinibvenetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2020-004910-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004910-37.